Absci Corporation Common Stock
ABSIAbsci Corporation is a biotechnology company specializing in artificial intelligence-driven drug discovery and development. It leverages its proprietary platform to streamline the creation of biologics and identify new therapeutic candidates efficiently, aiming to accelerate the journey from discovery to clinical trials.
Company News
Absci, a clinical-stage biotech company using generative AI for drug discovery, will report its Q3 2025 financial and operating results on November 12, 2025, via a webcast conference call.
Absci Corporation announced participation in upcoming healthcare investor conferences and plans to host a key opinion leader (KOL) seminar on its ABS-201 hair regrowth program, with an accelerated Phase 1/2a trial expected to begin in December 2025.
Absci Corp, a small AI biotech company, offers high-risk investment potential in drug discovery using generative AI, with multiple drug candidates in clinical trials and strategic partnerships with major pharma companies.
The global CADD market is experiencing rapid growth, projected to generate substantial revenue between 2025-2034, driven by technological innovations, AI integration, and increasing demand across pharmaceutical and research sectors.
Absci partnered with Oracle Cloud Infrastructure and AMD to accelerate AI-driven drug discovery, leveraging high-performance computing infrastructure for molecular simulations and antibody design.
